Abstract 1431P
Background
Neoadjuvant chemotherapy combined with immunotherapy (nCIT) is emerging as a promising strategy for treating patients with esophageal cancer. We aimed to develop a novel, voxel-level radiomics deep learning model to predict the pathological complete response (pCR) to nCIT in esophageal squamous cell carcinoma (ESCC).
Methods
We included 745 ESCC patients from three institutions, comprising a training set (N=500, institution 1), test-set-1 (N=86, institution 1), test-set-2 (N=34, institution 2), and test-set-3 (N=125, institution 3). All patients underwent nCIT and received a pathological evaluation post-surgery. A total of 104 distinct radiomic features were extracted from the tumor areas in CT images prior to nCIT. Features demonstrating predictive power with an area under the receiver operating characteristic curve (AUROC) exceeding 0.6 were retained. Each selected radiomics feature map, along with the original image, was input into a vision transformer model as a separate channel. The Shapley Additive exPlanations method was employed to visualize feature importance and identify predictive regions within the tumor, enhancing the model’s interpretability. For baseline comparison, we also constructed a clinical model using only clinical factors, and compared it against traditional radiomics and ResNet models.
Results
The voxel-level radiomics deep learning model achieved an AUC of 0.825 with an accuracy of 76.2% in test-set-1, 0.751 and 68.5% in test-set-2, and 0.819 with 78.1% in test-set-3, respectively. It demonstrated superior predictive performance compared to the clinical model, traditional radiomics model, and ResNet model.
Conclusions
This innovative and noninvasive voxel-level radiomics deep learning approach offers an efficient and accurate approach of predicting treatment response to nCIT in ESCC, potentially benefiting clinical decision-making.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Z. Zhang.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1406P - Interim response evaluation from a phase II study of capecitabine, oxaliplatin, and anti-PD-1 in dMMR esophagogastric cancer (AuspiCiOus trial)
Presenter: Joris Bos
Session: Poster session 17
1407P - Pan-immune-inflammation value predicts the survival of patients with esophageal squamous cell carcinoma receiving immunotherapy and chemoradiotherapy: A pooled-analysis of two phase II trials
Presenter: Xingyuan Cheng
Session: Poster session 17
1408P - DVDMS (Sinoporphyrin sodium)-mediated photodynamic therapy (PDT) vs treatment of physician’s choice in patients with advanced esophageal cancer (EC): Preliminary results of DYNA-Esophagus03, a randomized, open-labeled, multicenter phase IIIb study
Presenter: Jun Zhou
Session: Poster session 17
1409P - Advancing esophageal cancer radiotherapy: AS-NeSt's 3D predictive proficiency for personalized dose distribution
Presenter: Yanhua Duan
Session: Poster session 17
Resources:
Abstract
1410P - Efficacy of fruquintinib plus paclitaxel (F+PTX) in patients (pts) with prior immunotherapy (prior-IO): Subgroup analysis from FRUTIGA study
Presenter: Lin Shen
Session: Poster session 17
1411P - AI-powered immune phenotype predicts favorable outcomes of nivolumab (niv) plus chemotherapy (chemo) in advanced fgastric cancer (AGC): A multi-center real-world data analysis
Presenter: Hyung-don Kim
Session: Poster session 17
1412P - Intestinal microbiota as a biological marker for pre-neoplastic lesion in gastric cancer in Amazonas, Brazil
Presenter: ÁBNER PAZ
Session: Poster session 17
Resources:
Abstract
1413P - Multi-modal deep-learning model for real-time prediction of recurrence in early-stage esophageal cancer: A multi-modal approach
Presenter: Hyun Ae Jung
Session: Poster session 17
1414P - Iparomlimab and tuvonralimab (QL1706) with definitive chemoradiotherapy for locally advanced esophageal squamous cell carcinoma: An open-label phase II study
Presenter: Wencheng Zhang
Session: Poster session 17
1415P - Real-world data on the use of nivolumab plus chemotherapy for patients with metastatic GC/GEJC/EAC: A Canadian perspective
Presenter: Mustapha Tehfe
Session: Poster session 17